Apyx Medical upgraded to Buy from Neutral at BTIG

BTIG analyst Sam Eiber upgraded Apyx Medical (APYX) to Buy from Neutral with a $6 price target The firm cites positive early momentum with the Ayon launch, growing demand for skin tightening among consumers taking GLP-1s, and Apyx Medical’s expansion opportunities outside the U.S. for the upgrade. Accelerating growth and cost controls offer greater visibility into the company’s path to sustainable profitability, which had been a previous core concern, the analyst tells investors in a research note.